Results 11 to 20 of about 18,599 (272)

Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models. [PDF]

Cancer, 2020
Poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors exhibit promising activity against ovarian cancers, but their efficacy can be limited by acquired drug resistance.
Santiago-O'Farrill JM, Weroha SJ, Hou X, Oberg AL, Heinzen EP, Maurer MJ, Pang L, Rask P, Amaravadi RK, Becker SE, Romero I, Rubio MJ, Matias-Guiu X, Santacana M, Llombart-Cussac A, Poveda A, Lu Z, Bast RC.   +17 more
europepmc   +4 more sources

Do Not Forget Poly (Adenosine Diphosphate-Ribose) Polymerase Inhibitors in Ovarian Carcinosarcoma. [PDF]

Cureus, 2022
Ovarian carcinosarcoma (OCS) is a rare entity with a poor prognosis and without evidence-based therapy. Here, we report the case of a 55-year-old woman with a germline BRCA1 mutation and a stage IV OCS who was proposed olaparib maintenance therapy after ...
Magalhães D, Bartosch C, Abreu MH.
europepmc   +4 more sources

Positron Emission Tomography Imaging of Poly-(Adenosine Diphosphate-Ribose) Polymerase 1 Expression in Breast Cancer: A Nonrandomized Clinical Trial. [PDF]

JAMA Oncol, 2020
McDonald ES, Doot RK, Pantel AR, Farwell MD, Mach RH, Maxwell KN, Mankoff DA.   +6 more
europepmc   +3 more sources

Poly(adenosine diphosphate-ribose) polymerase as therapeutic target: lessons learned from its inhibitors. [PDF]

Oncotarget, 2017
Poly(ADP-ribose) polymerases are a family of DNA-dependent nuclear enzymes catalyzing the transfer of ADP-ribose moieties from cellular nicotinamide-adenine-dinucleotide to a variety of target proteins.
Cseh AM, Fábián Z, Sümegi B, Scorrano L.   +3 more
europepmc   +4 more sources

Kinetic Analysis and Metabolism of Poly(Adenosine Diphosphate-Ribose) Polymerase-1-Targeted ¹⁸F-Fluorthanatrace PET in Breast Cancer. [PDF]

J Nucl Med
Visual Abstract The poly(adenosine diphosphate–ribose) polymerase inhibitors (PARPi) have demonstrated efficacy in ovarian, breast, and prostate cancers, but current biomarkers do not consistently predict clinical benefit.
Young AJ, Pantel AR, Kiani M, Doot RK, Bagheri S, Pryma DA, Farwell MD, Li S, Lee H, Schubert EK, Secreto A, Zuckerman SP, Nayak A, Choi H, Carlin S, DeMichele A, Mankoff DA, Zhou R, Mach RH, McDonald ES.   +19 more
europepmc   +4 more sources

Role of Poly Adenosine Diphosphate Ribose Polymerase Inhibitors in Advanced Stage Ovarian Cancer. [PDF]

Cureus, 2018
Ovarian cancer is one of the leading causes of death from gynecologic cancers. In this present era of cancer treatment, therapeutic options for patients with advanced or recurrent ovarian cancer are limited.
Arora E, Masab M, Jindal V, Riaz I, Gupta S, Varadi G.   +5 more
europepmc   +4 more sources

The poly(adenosine diphosphate-ribose) polymerase inhibitor PJ34 reduces pulmonary ischemia-reperfusion injury in rats. [PDF]

Transplantation, 2014
Background Ischemia-reperfusion (I/R) injury after lung transplantation causes alveolar damage, lung edema, and acute rejection. Poly(adenosine diphosphate-ribose) polymerase (PARP) is a single-stranded DNA repair enzyme that induces apoptosis and ...
Hatachi G, Tsuchiya T, Miyazaki T, Matsumoto K, Yamasaki N, Okita N, Nanashima A, Higami Y, Nagayasu T.   +8 more
europepmc   +4 more sources

Poly(adenosine diphosphate‐ribose) polymerase inhibitor combinations in first‐line metastatic castrate‐resistant prostate cancer setting: a systematic review and m eta‐analysis [PDF]

BJU International, 2023
To compare radiographic progression‐free survival (rPFS), overall survival (OS), and treatment‐emergent adverse events (TEAEs) among patients with metastatic castrate‐resistant prostate cancer (mCRPC) receiving a combination of first‐line poly(adenosine ...
Rashid K. Sayyid, Zachary Klaassen, Alejandro Berlín, Soumyajit Roy, Leonardo R. Brandão, Rui Bernardino, Julián Chavarriaga, Di Jiang, Daniel E. Spratt, Neil Fleshner, Christopher J.D. Wallis   +10 more
openalex   +2 more sources

Unlocking Therapeutic Potential of Poly(Adenosine Diphosphate Ribose) Polymerase (PARP) Inhibitors in Metastatic Breast Cancer With BRCA Gene Mutations: A Narrative Review. [PDF]

Cureus, 2023
Breast cancer (BC), a significant global health concern, impacts millions of women worldwide. A key genetic factor in this disease is the presence of BReast CAncer gene (BRCA) mutations, which increase susceptibility to BC. This narrative review explores
Jain P.
europepmc   +2 more sources

Novel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibition [PDF]

Pharmacogenomics and Personalized Medicine, 2014
M William Audeh Division of Medical Oncology, Samuel Oschin Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA Abstract: Inhibitors of the poly(adenosine triphosphate-ribose) polymerase (PARP)-1 enzyme induce synthetic lethality in ...
Audeh MW
doaj   +2 more sources